CCR7 and neoplasm: For example, immune checkpoint therapy increases interferon gamma (IFNγ) production by PD-1+CD8+ T cells that co-localise with CCR7+ DCs in tumours (Supplementary Fig. 8k), which may activate tumour DCs32.